SCHEMBL22916952

SCHEMBL22916952

CCNC(=O)CCNS(=O)(=O)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 3/20 0.48
FAAH O00519 1/20 0.41
HTT P42858 1/20 0.38
ALDH1A1 P00352 4/20 0.37
CAPN1 P07384 1/20 0.35
GRIA4 P48058 1/20 0.35
USP2 O75604 1/20 0.35
MMP2 P08253 2/20 0.35
MMP9 P14780 2/20 0.35
MCL1 Q07820 1/20 0.34
CA12 O43570 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
EPHX2 P34913 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25514781 0.79 GRIA1 (0.50) GRIA1FAAHHTTALDH1A1GRIA4
SCHEMBL22917237 0.77 GRIA1 (0.52) GRIA1ALDH1A1GRIA4USP2
SCHEMBL23182182 0.76 GRIA1 (0.56) GRIA1ALDH1A1GRIA4CA12CA7
SCHEMBL2842451 0.76 GRIA1 (0.56) GRIA1HTTALDH1A1GRIA4CA12
SCHEMBL24571855 0.76 GRIA1 (0.40) GRIA1HTTALDH1A1KDM4EHPGD
SCHEMBL18396200 0.73 GRIA1 (0.52) GRIA1GRIA4CA12CA7CA9
SCHEMBL18396198 0.73 GRIA1 (0.52) GRIA1GRIA4CA12CA7CA9
SCHEMBL13610004 0.72 GRIA1 (0.75) GRIA1GRIA4
SCHEMBL14365950 0.72 GRIA1 (0.50) GRIA1ALDH1A1GRIA4
SCHEMBL12673154 0.71 KMT2A (0.58) FAAHALDH1A1MCL1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 GRIA1 4374/4885FAAH 4699/4885HTT 2265/4885
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 GRIA1 4374/4885FAAH 4699/4885HTT 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.